Neoadjuvant therapy for HER2-positive acantholytic squamous cell breast carcinoma: a case report

HER2-positive acantholytic squamous cell carcinoma (ASCC) of the breast is exceptionally rare, and its clinicopathologic features are poorly understood. The impact of neoadjuvant therapy on HER2-positive breast ASCC is unclear. Here we report on a 58-year-old woman who was diagnosed with HER2-positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cong, Jia, Jo, HyonSu, Zou, Na, Kong, LingXin, Ri, HyokJu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566270/
https://www.ncbi.nlm.nih.gov/pubmed/37534455
http://dx.doi.org/10.1177/03000605231187936
_version_ 1785118887699808256
author Cong, Jia
Jo, HyonSu
Zou, Na
Kong, LingXin
Ri, HyokJu
author_facet Cong, Jia
Jo, HyonSu
Zou, Na
Kong, LingXin
Ri, HyokJu
author_sort Cong, Jia
collection PubMed
description HER2-positive acantholytic squamous cell carcinoma (ASCC) of the breast is exceptionally rare, and its clinicopathologic features are poorly understood. The impact of neoadjuvant therapy on HER2-positive breast ASCC is unclear. Here we report on a 58-year-old woman who was diagnosed with HER2-positive ASCC of the right breast, who underwent neoadjuvant treatment with albumin-paclitaxel, carboplatin, and trastuzumab, and surgery. Neoadjuvant therapy was effective, with no recurrence or metastasis after 1.5 years of postoperative follow-up.
format Online
Article
Text
id pubmed-10566270
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-105662702023-10-12 Neoadjuvant therapy for HER2-positive acantholytic squamous cell breast carcinoma: a case report Cong, Jia Jo, HyonSu Zou, Na Kong, LingXin Ri, HyokJu J Int Med Res Case Reports HER2-positive acantholytic squamous cell carcinoma (ASCC) of the breast is exceptionally rare, and its clinicopathologic features are poorly understood. The impact of neoadjuvant therapy on HER2-positive breast ASCC is unclear. Here we report on a 58-year-old woman who was diagnosed with HER2-positive ASCC of the right breast, who underwent neoadjuvant treatment with albumin-paclitaxel, carboplatin, and trastuzumab, and surgery. Neoadjuvant therapy was effective, with no recurrence or metastasis after 1.5 years of postoperative follow-up. SAGE Publications 2023-08-03 /pmc/articles/PMC10566270/ /pubmed/37534455 http://dx.doi.org/10.1177/03000605231187936 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Reports
Cong, Jia
Jo, HyonSu
Zou, Na
Kong, LingXin
Ri, HyokJu
Neoadjuvant therapy for HER2-positive acantholytic squamous cell breast carcinoma: a case report
title Neoadjuvant therapy for HER2-positive acantholytic squamous cell breast carcinoma: a case report
title_full Neoadjuvant therapy for HER2-positive acantholytic squamous cell breast carcinoma: a case report
title_fullStr Neoadjuvant therapy for HER2-positive acantholytic squamous cell breast carcinoma: a case report
title_full_unstemmed Neoadjuvant therapy for HER2-positive acantholytic squamous cell breast carcinoma: a case report
title_short Neoadjuvant therapy for HER2-positive acantholytic squamous cell breast carcinoma: a case report
title_sort neoadjuvant therapy for her2-positive acantholytic squamous cell breast carcinoma: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566270/
https://www.ncbi.nlm.nih.gov/pubmed/37534455
http://dx.doi.org/10.1177/03000605231187936
work_keys_str_mv AT congjia neoadjuvanttherapyforher2positiveacantholyticsquamouscellbreastcarcinomaacasereport
AT johyonsu neoadjuvanttherapyforher2positiveacantholyticsquamouscellbreastcarcinomaacasereport
AT zouna neoadjuvanttherapyforher2positiveacantholyticsquamouscellbreastcarcinomaacasereport
AT konglingxin neoadjuvanttherapyforher2positiveacantholyticsquamouscellbreastcarcinomaacasereport
AT rihyokju neoadjuvanttherapyforher2positiveacantholyticsquamouscellbreastcarcinomaacasereport

Ejemplares similares